Episode

Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli

Podcast
Eyewire News: The Podcast
Published
Feb 18, 2026
Duration seconds
362
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/BMCL5573269039.mp3
Audio
https://traffic.megaphone.fm/BMCL5573269039.mp3
JSON
/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/ocular-releases-phase-3-data-for-wet-amd-candidate-axpaxli
Markdown
/podcast/eyewire-news-the-podcast-7055536/ocular-releases-phase-3-data-for-wet-amd-candidate-axpaxli.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/ocular-releases-phase-3-data-for-wet-amd-candidate-axpaxli/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/ocular-releases-phase-3-data-for-wet-amd-candidate-axpaxli.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology. Learn more about your ad choices. Visit megaphone.fm/adchoices